SEC Form 4

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

3235-0287 OMB Number: Estimated average burden hours per response: 0.5

			or Sec		vestment Con	pany Act of 1940					
1. Name and Address of Reporting Person [*] CHASE ANTHONY R				r Name and Ticker Ita Therapeut			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) 215 FIRST STR	(First) REET, SUITE 7	(Middle)	3. Date 06/04/	of Earliest Transac 2013	tion (Month/D	ay/Year)		Officer (give title below)		(specify	
(Street) CAMBRIDGE	МА	02412	4. If Am	endment, Date of C	Driginal Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Form filed by One Form filed by Mor Person	e Reporting Pers	on	
(City)	(State)	(Zip)									
	-	Table I - Nor	-Derivative S	ecurities Acqu	uired, Disp	osed of, or Benefi	cially (Owned			
1. Title of Security (Instr. 3) Date (Month/I				2A. Deemed Execution Date, if any	3. Transaction Code (Instr.	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial	

	(Month/Day/Year)	if any (Month/Day/Year)	Code (Instr. 8)		·,					Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Common Stock ⁽¹⁾	06/04/2013		A		1,000 ⁽²⁾	A	\$0.00	18,244	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Inst 3, 4 and 5)		ve es d ed nstr.	6. Date Exerci Expiration Dat (Month/Day/Ye	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$34.92	06/04/2013		A		20,000		06/04/2014 ⁽³⁾	06/04/2023	Common Stock ⁽¹⁾	20,000	\$0	20,000	D	

Explanation of Responses:

1. On June 6, 2013, Sarepta Therapeutics, Inc., a Delaware corporation, became the successor of Sarepta Therapeutics, Inc., an Oregon corporation, pursuant to a merger. The merger had the effect of changing the state of incorporation of Sarepta Therapeutics, Inc. from Oregon to Delaware, but did not alter the proportionate interests of security holders.

2. Grant of restricted stock, which shall vest in full on the anniversary date of the grant.

3. This option will vest at a rate of 25% annually over four years beginning on the first anniversary of the date of grant.

<u>By: David Tyronne Howton</u>	06/0			
For: Anthony R. Chase	06/0			

** Signature of Reporting Person

6/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.